TG Therapeutics (TGTX) Reports Launch of ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ (umbralisib)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
UPDATE: Goldman Sachs Starts TG Therapeutics (TGTX) at Neutral
April 20, 2021 2:45 AM EDT(Updated - April 20, 2021 3:28 AM EDT)
Goldman Sachs analyst Graig Suvannavejh initiates coverage on TG Therapeutics (NASDAQ: TGTX) with a Neutral rating and a price target of $50.00.
The analyst comments "TGTX is a US biopharmaceutical company, with a diversified pipeline that features two... More
TG Therapeutics (TGTX) PT Raised to $89 at H.C. Wainwright
April 19, 2021 6:32 AM EDTH.C. Wainwright analyst Edward P. White raised the price target on TG Therapeutics (NASDAQ: TGTX) to $89.00 (from $79.00) while maintaining a Buy rating.... More
